TARA - NASDAQ
Protara Therapeutics, Inc.
$4.22
-1.2%Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
At a Glance
Live Snapshottara
Additional Paid-In Capital
Last Annual Value
498.69M
3-Year CAGR
24%
5-Year CAGR
15%
10-Year CAGR
10%
Protara Therapeutics, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Protara Therapeutics, Inc. NASDAQ:TARA | 498.69M | 22.9% | 14.3% | 9.7% | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 1.04B | 7.9% | 5.3% | 13.7% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 702.98M | 17.8% | 10.9% | 32.5% | |
 Immuneering Corporation NASDAQ:IMRX | 498.66M | 25.2% | 18.3% | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 496.47M | 6.4% | 7.1% | N/A | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 751.68M | 2.7% | 8.2% | N/A | |
 Invivyd, Inc. NASDAQ:IVVD | 1.20B | 9.6% | 7.1% | N/A | |
 Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 416.08M | 9.5% | 34.4% | N/A | |
 Codexis, Inc. NASDAQ:CDXS | 657.29M | 4.0% | 3.6% | 7.8% | |
 OmniAb, Inc. NASDAQ:OABI | 433.18M | 7.0% | N/A | N/A | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 1.61B | 2.6% | 3.8% | 10.8% |
Protara Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your TARA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.